Clinical Trial Detail

NCT ID NCT03686488
Title TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Ramucirumab + Trifluridine-tipiracil hydrochloride

Age Groups: senior adult

No variant requirements are available.